Yahoo Finance

CFRX: Planning for Phase 3 Trial of Exebacase in S. Aureus Bacteremia…

ContraFect Corp. (CFRX) is developing exebacase (CF-301), the company’s lead lysin product, for the treatment of bacteremia caused by Staphylococcus aureus infections. Lysins are naturally occurring ...
Yahoo Finance

ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphylococcus aureus Bacteremia at IDWeek™ 2021

YONKERS, N.Y., Sept. 29, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents ...
Business Insider

ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal

YONKERS, N.Y., May 31, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for ...
Monthly Prescribing Reference

Exebacase Gains Breakthrough Therapy Status for MRSA Bacteremia, Including Right-Sided Endocarditis

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to exebacase (ContraFect) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, ...
Business Insider

ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia

YONKERS, N.Y., Sept. 06, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody ...
Seeking Alpha

Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect’s Direct Lytic Agents (DLAs) to Address MRSA Infections

YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (CFRX) (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic ...